Breaking News Instant updates and real-time market news.

BPTS

Biophytis

$8.90 /

+0.05 (+0.56%)

05:11
09/17/21
09/17
05:11
09/17/21
05:11

Biophytis reports 1H EPS (EUR 0.14) vs, (EUR 0.25) last year

Cash and cash equivalents as of June 30, were EUR 23M, an increase of EUR 4.7M as compared to EUR 18.3M as of December 31, 2020, and an increase of EUR 10.8M vs EUR 12.2M as of June 2020. Stanislas Veillet, CEO of Biophytis, said: "During the first half of 2021 Biophytis reached a major milestone with positive results from the SARA-INT Phase 2 trial, which demonstrated the efficacy of Sarconeos (BIO101) in sarcopenia. Indeed Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the study. We are now committed to progressing Sarconeos (BIO101) into phase 3 for this indication either alone or through partnerships with pharmaceutical companies. Moreover, recommendations from DMC a few days ago for our COVA study to continue without any modification, based upon efficacy results in the promising zone following the second interim analysis, are very encouraging. We hope that Sarconeos (BIO101) will become one of the first drug candidates able to restore breathing capabilities for hospitalized patients in severe conditions, and therefore avoiding their admission to ICUs. The whole Company is now focused on the next milestones, ie complete the trial as soon as possible, as well as industrial scaling up and regulatory approvals in Europe, USA and Brazil. We want to be ready for commercialization of our Sarconeos (BIO101) in COVID-19 first half of 2022. From a financial perspective, our cash position was strengthened following our successful IPO in the US market. We also closed a new ORNANE contract with Atlas up to 32MEUR securing the outlook of the Company's financing."

  • 10

    Feb

TODAY'S FREE FLY STORIES

Periodicals
Gentherm a cheap way to play EV boom, Barron's says » 09:36
11/27/21
11/27
09:36
11/27/21
09:36
THRM

Gentherm

$83.98 /

-4.06 (-4.61%)

Gentherm, a small-cap…

Gentherm, a small-cap auto supplier, has 60% of the global market for heated and air-conditioned seats, towering over its next competitor at 10%, Daren Fonda writes in this week's edition of Barron's. Auto production is ailing due to a global semiconductor shortage. But the supply chain should ease up in the second half of 2022, giving Gentherm a sales lift, the author contends. Climate-controlled seating is expanding to the mass market-growing from 4% of U.S. new vehicles in 2013 to 18% in 2020. More important, Gentherm has a shot at the fastest-growing part of the car market, namely electric vehicles, the publication adds. Reference Link

ShowHide Related Items >><<
THRM Gentherm
$83.98 /

-4.06 (-4.61%)

THRM Gentherm
$83.98 /

-4.06 (-4.61%)

10/28/21 Roth Capital
Gentherm price target lowered to $85 from $92 at Roth Capital
10/27/21
Fly Intel: Top five analyst initiations
10/27/21 Seaport Global
Gentherm initiated with a Buy at Seaport Global
09/22/21
Fly Intel: Top five analyst initiations
THRM Gentherm
$83.98 /

-4.06 (-4.61%)

Periodicals
Nio, Xpeng, Li Auto look set to grow on bigger sales, Barron's says » 09:33
11/27/21
11/27
09:33
11/27/21
09:33
NIO

Nio

$39.88 /

-1.55 (-3.74%)

, XPEV

XPeng

$51.01 /

-3.43 (-6.30%)

, LI

Li Auto

$32.66 /

-0.005 (-0.02%)

Buying growth stocks when…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

LI Li Auto
$32.66 /

-0.005 (-0.02%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

11/23/21 Citi
Citi says Nio shares oversold after offering, keeps $87 target
11/11/21 Mizuho
Nio price target lowered to $65 from $67 at Mizuho
11/11/21 Citi
Nio price target raised to $87 from $70 at Citi
11/04/21 Deutsche Bank
Nio price target raised to $70 from $60 at Deutsche Bank
XPEV XPeng
$51.01 /

-3.43 (-6.30%)

11/24/21 BofA
XPeng price target raised to $66 from $63 at BofA
11/24/21 Citi
XPeng price target raised to $92 from $87 at Citi
11/11/21 Citi
XPeng price target raised to $87 from $53.40 at Citi
10/28/21
Fly Intel: Top five analyst initiations
LI Li Auto
$32.66 /

-0.005 (-0.02%)

11/11/21 Citi
Li Auto price target raised to $200 from $165 at Citi
10/28/21 Bernstein
Bernstein starts Li Auto at Outperform, sees EVs as 'future' of Chinese autos
10/28/21 Bernstein
Li Auto initiated with an Outperform at Bernstein
XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

LI Li Auto
$32.66 /

-0.005 (-0.02%)

  • 13
    Aug
  • 14
    Dec
  • 09
    Dec
  • 04
    Dec
XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

LI Li Auto
$32.66 /

-0.005 (-0.02%)

XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

LI Li Auto
$32.66 /

-0.005 (-0.02%)

Periodicals
IBM finally growing again, stock a big bargain, Barron's says » 09:27
11/27/21
11/27
09:27
11/27/21
09:27
IBM

IBM

$115.50 /

-1.21 (-1.04%)

, MSFT

Microsoft

$329.70 /

-8.13 (-2.41%)

Investors have…

Investors have understandably forsaken Big Blue, but it may be time to start paying attention to it again, Savitz writes in this week's edition of Barron's. IBM (IBM) is repairing its reputation with a new CEO who is making serious and lasting changes to its structure and ambitions, the author notes. For investors who missed Microsoft's (MSFT) turnaround, IBM could offer a second chance. Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

10/28/21 Credit Suisse
IBM assumed with an Outperform at Credit Suisse
10/21/21 Morgan Stanley
IBM's Q3 'a pause on the path to improving growth,' says Morgan Stanley
10/06/21 Evercore ISI
IBM removed from Tactical Outperform list at Evercore ISI
10/05/21 Credit Suisse
IBM price target raised to $176 from $167 at Credit Suisse
MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

11/22/21 Wells Fargo
Wells Fargo starts Microsoft with Overweight, $400 target on 'bright future'
11/22/21 Wells Fargo
Microsoft initiated with an Overweight at Wells Fargo
11/19/21 UBS
Zoom Video price target lowered to $285 from $315 at UBS
11/16/21 Credit Suisse
Microsoft assumed with an Outperform at Credit Suisse
MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

On The Fly
Opening Day: Aeroclean shares jump on first trading day » 09:17
11/27/21
11/27
09:17
11/27/21
09:17
AERC

Aeroclean

$81.55 /

+5.05 (+6.60%)

, RGF

The Real Good Food Company

$9.11 /

-0.15 (-1.62%)

, IOBT

IO Biotech

$7.82 /

+0.6 (+8.31%)

, MYNZ

Mainz Biomed

$9.80 /

-0.28 (-2.78%)

, CIAN

Cian

$14.90 /

-0.1 (-0.67%)

, NRDS

NerdWallet

$22.56 /

-0.18 (-0.79%)

, ARHS

Arhaus

$10.14 /

+0.075 (+0.75%)

, CDRE

Cadre

$19.40 /

-0.1 (-0.51%)

, EVO

Evotec SE

$23.91 /

+0.69 (+2.97%)

, MDXH

MDxHealth

$10.07 /

+0.86 (+9.34%)

, SOPA

Society Pass

$11.10 /

-1.96 (-15.01%)

, STRN

Stran & Company

$3.10 /

-0.13 (-4.02%)

, TCBX

Third Coast Bancshares

$27.57 /

-0.23 (-0.83%)

, NUVO

Nuvo Group

/

+

, AUST

Austin Gold

/

+

, CHO

Chobani

/

+

, CAST

FreeCast

/

+

, IOT

Samsara

/

+

, KETR

Keter

/

+

, QNIU

Qiniu

/

+

, BABA

Alibaba

$133.00 /

-3.62 (-2.65%)

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

Shares of Aeroclean…

ShowHide Related Items >><<
STRN Stran & Company
$3.10 /

-0.13 (-4.02%)

IOT Samsara
/

+

CDRE Cadre
$19.40 /

-0.1 (-0.51%)

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

AERC Aeroclean
$81.55 /

+5.05 (+6.60%)

AERC Aeroclean
$81.55 /

+5.05 (+6.60%)

RGF The Real Good Food Company
$9.11 /

-0.15 (-1.62%)

IOBT IO Biotech
$7.82 /

+0.6 (+8.31%)

MYNZ Mainz Biomed
$9.80 /

-0.28 (-2.78%)

CIAN Cian
$14.90 /

-0.1 (-0.67%)

NRDS NerdWallet
$22.56 /

-0.18 (-0.79%)

ARHS Arhaus
$10.14 /

+0.075 (+0.75%)

CDRE Cadre
$19.40 /

-0.1 (-0.51%)

EVO Evotec SE
$23.91 /

+0.69 (+2.97%)

MDXH MDxHealth
$10.07 /

+0.86 (+9.34%)

SOPA Society Pass
$11.10 /

-1.96 (-15.01%)

STRN Stran & Company
$3.10 /

-0.13 (-4.02%)

TCBX Third Coast Bancshares
$27.57 /

-0.23 (-0.83%)

NUVO Nuvo Group
/

+

AUST Austin Gold
/

+

CHO Chobani
/

+

CAST FreeCast
/

+

IOT Samsara
/

+

KETR Keter
/

+

QNIU Qiniu
/

+

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

11/24/21
Fly Intel: Top five analyst downgrades
11/24/21 Argus
Alibaba downgraded to Hold from Buy at Argus
11/23/21 Needham
Alibaba price target lowered to $230 from $330 at Needham
11/19/21 Benchmark
Alibaba price target lowered to $245 from $270 at Benchmark
AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

  • 24
    Nov
  • 24
    Nov
  • 09
    Nov
  • 09
    Nov
  • 09
    Nov
  • 05
    Nov
  • 05
    Nov
  • 05
    Nov
  • 04
    Nov
  • 04
    Nov
  • 04
    Nov
  • 04
    Nov
  • 04
    Nov
  • 04
    Nov
BABA Alibaba
$133.00 /

-3.62 (-2.65%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

STRN Stran & Company
$3.10 /

-0.13 (-4.02%)

RGF The Real Good Food Company
$9.11 /

-0.15 (-1.62%)

MDXH MDxHealth
$10.07 /

+0.86 (+9.34%)

KETR Keter
/

+

CHO Chobani
/

+

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

NRDS NerdWallet
$22.56 /

-0.18 (-0.79%)

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

General news
Fed's Bostic played down risks from the new Omicron variant » 17:40
11/26/21
11/26
17:40
11/26/21
17:40
$ECON

Economic Data

/

+

Fed's Bostic played…

Fed's Bostic played down risks from the new Omicron variant and its impact on the economy in a Fox New interview. Though there could be some slowing in overall activity, he doubted it would be as much as with Delta. He noted there is a lot of momentum in the economy and added it is certainly possible the FOMC could hike rates twice in 2022, stressing the Fed is not going to let inflation get out of control. He remains "very open" to speeding up the pace of the slowing in asset purchases. He sees late Q1 or early Q2 as a possible timeframe for ending purchases. Bostic is a voter this year and was on the dovish side of the spectrum until the last few months as inflation remained elevated.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Treasury Market Summary » 17:30
11/26/21
11/26
17:30
11/26/21
17:30
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: it was the best of days and the worst of days in over a year for Treasuries and equities, respectively. Indeed "Black Friday" took on a new connotation as Wall Street took an ominous spin lower on fears over the new covid strain, Omicron. Stocks plunged and all of the major indexes posted declines of better than -2.2% as reopening and reflation trades were crushed. It was the largest one-day drop for the Dow since October 2020. But, that saw cash surge back into the safety of bonds with yields dropping dramatically, taking the 10-year rate back south of the 1.50% mark. It was the largest single day decline in the yield since March 2020 when covid first hit the markets. Fears over an aggressive shift from the FOMC to a more hawkish stance were slashed too. Expectations the Fed could speed up its pace of tapering as soon as the December 14-15 meeting due to the pick up in inflation weighed heavily on the money markets and bonds earlier this week. But they were sharply undone today with rate liftoff pushed back to September 2022, from June (and even May). It was a shortened session after the Thanksgiving holiday, but volume was solid.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet reserve bank credit $24.8B  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet total assets $6.8B  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet level $8.682T  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Technical Analysis
NASDAQ market internals summary » 16:23
11/26/21
11/26
16:23
11/26/21
16:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 919 / Declining Issues: 3632 -- for a ratio of 0.3 to 1. Advancing Volume: 1,006,406,000 / Declining Volume: 2,433,493,000 -- for a ratio of 0.4 to 1. New 52-Week Highs: 35 / New 52-Week Lows: 349.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 16:22
11/26/21
11/26
16:22
11/26/21
16:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 469 / Declining Issues: 2860 -- for a ratio of 0.2 to 1. Advancing Volume: 346,472,000 / Declining Volume: 3,140,522,000 -- for a ratio of 0.1 to 1. New 52-Week Highs: 21 / New 52-Week Lows: 210.

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 16:13
11/26/21
11/26
16:13
11/26/21
16:13
SNOW

Snowflake

$361.94 /

+6.655 (+1.87%)

, CRWD

Crowdstrike

$233.73 /

+2.93 (+1.27%)

, SPLK

Splunk

$125.25 /

+0.2 (+0.16%)

, VEEV

Veeva

$288.19 /

-2.64 (-0.91%)

Technology Analysts…

Technology Analysts Keirstead & Rocha provide a recap of Snowflake, Crowdstrike, Splunk and Veeva reported earnings on an Analyst/Industry conference call to be held on December 2 at 8:30 am.

ShowHide Related Items >><<
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

11/19/21
Fly Intel: Top five analyst downgrades
11/19/21 Rosenblatt
Snowflake downgraded to Neutral on valuation at Rosenblatt
11/19/21 Rosenblatt
Snowflake downgraded to Neutral from Buy at Rosenblatt
11/16/21 Credit Suisse
Snowflake initiated with an Outperform at Credit Suisse
CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

11/24/21 Deutsche Bank
Crowdstrike price target lowered to $300 from $320 at Deutsche Bank
11/18/21
Fly Intel: Top five analyst initiations
11/18/21 DA Davidson
Crowdstrike initiated with a Buy at DA Davidson
11/15/21
Fly Intel: Top five analyst initiations
SPLK Splunk
$125.25 /

+0.2 (+0.16%)

11/17/21 Argus
Argus 'surprised' by Splunk's 'abrupt' CEO dismissal
11/16/21 Mizuho
Splunk price target lowered to $165 from $175 at Mizuho
11/16/21 Credit Suisse
Splunk initiated with an Outperform at Credit Suisse
11/16/21 Deutsche Bank
Splunk price target lowered to $155 from $180 at Deutsche Bank
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

10/01/21 Stifel
Veeva assumed with a Buy at Stifel
09/03/21 SVB Leerink
Veeva price target raised to $296 from $294 at SVB Leerink
09/02/21 UBS
Veeva price target raised to $320 from $270 at UBS
09/02/21 Baird
Veeva price target raised to $349 from $340 at Baird
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

  • 16
    Mar
CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 16:08
11/26/21
11/26
16:08
11/26/21
16:08
CRM

Salesforce

$283.00 /

-6.155 (-2.13%)

, ZS

Zscaler

$337.00 /

-5.25 (-1.53%)

Technology Analysts…

Technology Analysts provide a recap of salesforce.com and Zscaler reported earnings on an Analyst/Industry conference call to be held on December 1 at 8:30 am.

ShowHide Related Items >><<
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

11/23/21 BofA
Salesforce price target raised to $360 from $330 at BofA
11/23/21 Jefferies
Salesforce price target raised to $360 from $325 at Jefferies
11/23/21 Citi
Salesforce price target raised to $308 from $280 at Citi
11/22/21 Atlantic Equities
Atlantic Equities assumes 'low-risk' Salesforce at Overweight
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

11/24/21 Deutsche Bank
Zscaler price target raised to $400 from $325 at Deutsche Bank
11/16/21 Credit Suisse
Zscaler initiated with an Outperform at Credit Suisse
11/15/21 Mizuho
Zscaler price target raised to $385 from $320 at Mizuho
11/09/21 BTIG
Zscaler price target raised to $401 from $324 at BTIG
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

Hot Stocks
Moderna testing existing and new variant-specific vaccine candidates for Omicron » 15:37
11/26/21
11/26
15:37
11/26/21
15:37
MRNA

Moderna

$331.10 /

+57.83 (+21.16%)

Moderna announced updates…

Moderna announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529, or "Omicron," variant. "The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape. The combination of mutations represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity. A booster dose of an authorized vaccine represents the only currently available strategy for boosting waning immunity. The Moderna COVID-19 vaccine - mRNA-1273 - is authorized as a booster for many populations at the 50 microgram dose level. The Company is working rapidly to test the ability of the current vaccine dose to neutralize the Omicron variant and data is expected in the coming weeks. Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern. This strategy includes three levels of response should the currently authorized 50 microgram booster dose of mRNA-1273 prove insufficient to boost waning immunity against the Omicron variant," the company stated. Moderna said it has already tested a higher dose booster of mRNA-1273, 100 microgram, in healthy adults. Moderna has completed dosing of 306 participants in a safety and immunogenicity study of this high dose booster. The 100 microgram dose of mRNA-1273 has also recently been studied by the National Institutes of Health in the U.S. and has generally resulted in the highest neutralizing titers against prior SARS-CoV-2 strains. Moderna is working to rapidly test sera from its high dose booster recipients in neutralizing assays to determine if the 100 microgram dose provides superior neutralizing protection against Omicron. Second, Moderna is already studying two multi-valent booster candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant. The first candidate, mRNA-1273.211, includes several mutations present in the Omicron variant that were also present in the Beta variant of concern. The company has completed dosing in a potentially pivotal safety and immunogenicity study of mRNA-1273.211 at the 50 microgram and 100 microgram dose levels. A second multi-valent candidate, mRNA-1273.213, includes many of the mutations present in the Omicron variant that were also present in the Beta and Delta variants. The company has completed dosing at the 100 microgram dose level and also plans to explore the 50 microgram dose level in approximately 584 participants. Moderna will rapidly expand testing of sera from completed and ongoing multi-valent booster studies to determine if these multi-valent candidates are able to provide superior neutralizing protection against Omicron. Third, Moderna will rapidly advance an Omicron-specific booster candidate, mRNA-1273.529. This candidate is part of the company's strategy to advance variant-specific candidates for a subset of variants of significant concern. During 2021 this has already included Beta- and Delta-specific boosters. The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60-90 days. "From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves. The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant. We have three lines of defense that we are advancing in parallel: we have already evaluated a higher dose booster of mRNA-1273, second, we are already studying two multi-valent booster candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant and data is expected in the coming weeks, and third, we are rapidly advancing a Omicron-specific booster candidate," said Stephane Bancel, CEO of Moderna.

ShowHide Related Items >><<
MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

11/26/21 Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

Conference/Events
UBS biotechnology analysts to hold an analyst/industry conference call » 15:29
11/26/21
11/26
15:29
11/26/21
15:29

Biotech Analysts Merle…

Biotech Analysts Merle & Rajavelu provide perspectives on the upcoming Phase 3 Data readouts for ATTR-CM (Transthyretin Amyloid Cardiomyopathy) data readouts on an Analyst/Industry conference call to be held on November 30 at 10 am.

Technical Analysis
NASDAQ market internals summary » 15:23
11/26/21
11/26
15:23
11/26/21
15:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 919 / Declining Issues: 3632 -- for a ratio of 0.3 to 1. Advancing Volume: 1,002,836,000 / Declining Volume: 2,418,765,000 -- for a ratio of 0.4 to 1. New 52-Week Highs: 35 / New 52-Week Lows: 349.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 15:22
11/26/21
11/26
15:22
11/26/21
15:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 469 / Declining Issues: 2860 -- for a ratio of 0.2 to 1. Advancing Volume: 344,464,000 / Declining Volume: 3,113,466,000 -- for a ratio of 0.1 to 1. New 52-Week Highs: 21 / New 52-Week Lows: 210.

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 15:20
11/26/21
11/26
15:20
11/26/21
15:20

Technology Analysts…

Technology Analysts Keirstead and Rocha provide an update on the Technology sector on an Analyst/Industry conference call to be held on November 30 at 9 am.

Conference/Events
UBS restaurants analyst to hold analyst/industry conference call » 15:15
11/26/21
11/26
15:15
11/26/21
15:15

Restaurants Analyst…

Restaurants Analyst Geiger, along with a quick serve restaurant coffee franchisee, discuss the industry on an Analyst/Industry conference call to be held on November 29 at 11 am.

Conference/Events
UBS consumer goods analyst to hold analyst/industry conference call » 15:12
11/26/21
11/26
15:12
11/26/21
15:12

Consumer Goods Analyst…

Consumer Goods Analyst Sole provides a recap of the Black Friday Weekend on an Analyst/Industry conference call to be held on November 29 at 10 am.

Conference/Events
Cowen pharma/biotech analysts to hold an analyst/industry conference call » 15:03
11/26/21
11/26
15:03
11/26/21
15:03

Pharmaceuticals Analyst…

Pharmaceuticals Analyst Scala and Biotech Analyst Rodriguez-Dumont discuss the current status and future opportunities for women's health on an Analyst/Industry conference call to be held on December 3 at 10 am.

Conference/Events
Cowen financial services analyst to hold analyst/industry conference call » 14:59
11/26/21
11/26
14:59
11/26/21
14:59

Head of Equity…

Head of Equity Derivatives Forman and Financial Services Analyst Seiberg discuss Cryptocurrency and Digital Assets with a look back at 2021 and thoughts for 2022 on an Analyst/Industry conference call to be held on December 2 at 11 am.

Conference/Events
Cowen media & entertainment analyst to hold analyst/industry conference call » 14:54
11/26/21
11/26
14:54
11/26/21
14:54
DISCA

Discovery

$24.72 /

-0.47 (-1.87%)

Media & Entertainment…

Media & Entertainment Analyst Creutz and TMT Policy Analyst Gallant discusses the Discovery-Time Warner merger-spin including the fundamental value, regulatory risk and when-issued market on an Analyst/Industry conference call to be held on December 2 at 11 am.

ShowHide Related Items >><<
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

11/08/21 Macquarie
Macquarie upgrades Discovery to Outperform, raises target to $40
11/08/21 Macquarie
Discovery upgraded to Outperform from Neutral at Macquarie
11/01/21 Bernstein
Bernstein upgrades Discovery to Market Perform, lowers target to $26
11/01/21 Bernstein
Discovery upgraded to Market Perform from Underperform at Bernstein
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

  • 14
    Apr
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

Conference/Events
Cowen ESG & restaurant analysts hold analyst/industry conference call » 14:47
11/26/21
11/26
14:47
11/26/21
14:47

ESG Policy Analyst Miller…

ESG Policy Analyst Miller and Restaurant Analyst Charles discuss how today shapes tomorrow and focus on the Restaurant Industry's ESG framework on an Analyst/Industry conference call to be held on December 1 at 11 am.

General news
FX Action: USD-JPY » 14:40
11/26/21
11/26
14:40
11/26/21
14:40
$ECON

Economic Data

/

+

FX Action: USD-JPY…

FX Action: USD-JPY revealed its safe-haven credentials, falling to near three-week lows of 113.05 on the back of the new Covid variant, and the slide in Treasury yields. The pairing had topped at 115.34 overnight. With answers on the new variant likely to take a couple of weeks, the yen may remain in favor for now.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.